Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists|July 31, 2013
AKT, EGFR, C-ErbB-2, and C-kit expression in uterine carcinosarcomaOzlen Saglam, Seema Husain, Gokce Toruner
Biomed Research International|April 16, 2015
Evolution of genetic techniques: past, present, and beyondAsude Alpman Durmaz, Emin Karaca, Urszula Demkow, et al.
Human Pathology|April 29, 2014
Matricellular protein CCN1 (CYR61) expression is associated with high-grade ductal carcinoma in situOzlen Saglam, Feng Dai, Seema Husain, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|January 20, 2010
Detection of low-level mosaicism and placental mosaicism by oligonucleotide array comparative genomic hybridizationStuart A Scott, Ninette Cohen, Tracy Brandt, et al.
Pediatric Blood & Cancer|March 10, 2011
Expression profiling reveals MSX1 and EphB2 expression correlates with the invasion capacity of Wilms tumorsAlbert Chetcuti, Safiye Aktas, Nicole Mackie, et al.
Annals of Diagnostic Pathology|August 29, 2024
From the archives of MD Anderson Cancer Center: Composite mantle cell lymphoma and lymphoplasmacytic lymphoma involving bone marrow at presentationYiannis Petros Dimopoulos, Beenu Thakral, Pei Lin, et al.
Leukemia & Lymphoma|December 31, 2021
Statins enhance the chemosensitivity of R-CHOP in diffuse large B-cell lymphomaSushanth Gouni, Paolo Strati, Gokce Toruner, et al.
Annals of Hematology|August 25, 2020
LPL deletion is associated with poorer response to ibrutinib-based treatments and overall survival in TP53-deleted chronic lymphocytic leukemiaWei Liu, Jan A Burger, Jie Xu, et al.
Clinical Lung Cancer|December 8, 2020
MET Amplification (MET/CEP7 Ratio ≥ 1.8) Is an Independent Poor Prognostic Marker in Patients With Treatment-naive Non-Small-cell Lung CancerWei Yin, Joanne Cheng, Zhenya Tang, et al.
Experimental and Molecular Pathology|November 15, 2020
Acquired MET amplification in non-small cell lung cancer is highly associated with the exposure of EGFR inhibitors and may not affect patients' outcomeWei Yin, Wei Liu, Ming Guo, et al.
Pageof 3